Patents by Inventor Lorne Erdile

Lorne Erdile has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080089911
    Abstract: Immununological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.
    Type: Application
    Filed: May 18, 2007
    Publication date: April 17, 2008
    Inventors: Robert Becker, Robert Huebner, Maryann Gray, Karen Biscardi, Lorne Erdile, Bruno Guy
  • Publication number: 20070237795
    Abstract: A method of preserving haptenized tumor cells is described. The method employs a freezing medium containing an effective amount of sucrose and human serum albumin in an isotonic buffered saline solution. Cryogenically preserving haptenized cells in such a medium has been found to maintain the integrity of the tumor cells during storage. The haptenized tumor cells also retain cell-associated antigens and haptens, and are as immunogenic, i.e., capable of inducing immunotherapeutic response, as fresh vaccine in a mouse model of metastatic disease. In a specific embodiment, haptenized cells are exposed to a solution of 8% sucrose, 10% human serum albumin in Hank's buffered solution, and then frozen to ?80° C. overnight and then stored in a liquid nitrogen freezer. Methods of storing haptenized tumor cells and compositions are also provided.
    Type: Application
    Filed: June 13, 2007
    Publication date: October 11, 2007
    Inventors: David Berd, Lorne Erdile, Margalit Mokyr
  • Publication number: 20060110408
    Abstract: Immununological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.
    Type: Application
    Filed: July 1, 2005
    Publication date: May 25, 2006
    Inventors: Robert Becker, Robert Huebner, Maryann Gray, Karen Biscardi, Lorne Erdile, Bruno Guy
  • Publication number: 20050233301
    Abstract: A method of preserving haptenized tumor cells is described. The method employs a freezing medium containing an effective amount of sucrose and human serum albumin in an isotonic buffered saline solution. Cryogenically preserving haptenized cells in such a medium has been found to maintain the integrity of the tumor cells during storage. The haptenized tumor cells also retain cell-associated antigens and haptens, and are as immunogenic, i.e., capable of inducing immunotherapeutic response, as fresh vaccine in a mouse model of metastatic disease. In a specific embodiment, haptenized cells are exposed to a solution of 8% sucrose, 10% human serum albumin in Hank's buffered solution, and then frozen to ?80° C. overnight and then stored in a liquid nitrogen freezer. Methods of storing haptenized tumor cells and compositions are also provided.
    Type: Application
    Filed: December 9, 2004
    Publication date: October 20, 2005
    Inventors: David Berd, Lorne Erdile, Margalit Mokyr
  • Publication number: 20050171343
    Abstract: Heterologous lipidated proteins formed recombinantly are disclosed and claimed. The expression system can be E. coli. The heterologous lipidated protein has a leader sequence which does not naturally occur with the protein portion of the lipidated protein. The lipidated protein can have the Borrelia OspA leader sequence. The protein portion can be OspC, PspA, UreA, Ure B, or a fragment thereof. Methods and compositions for forming and employing the proteins are also disclosed and claimed.
    Type: Application
    Filed: February 6, 2003
    Publication date: August 4, 2005
    Inventors: Robert Huebner, Lorne Erdile, Donald Warakomski, Robert Becker, Maryann Gray, Derek Pyle
  • Patent number: 6183752
    Abstract: Disclosed and claimed are compositions and methods for therapy and/or prevention of restenosis and/or atherosclerosis. The compositions can include an agent for decreasing viral load of cytomegalovirus, such as an immunological composition or vaccine against cytomegalovirus (CMV) containing at least one epitope of interest of CMV and/or an expression system which expresses at least one epitope of interest of CMV. Such compositions can include at least one epitope of p53. Alternatively, the compositions can include at least one epitope of p53 and/or an expression system which expresses the epitope. The methods can include administering the compositions to a patient in need of such therapy and/or prevention.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: February 6, 2001
    Assignees: Pasteur Merieux Serums et Vaccins, The United States of America as represented by the Department of Health and Human Services
    Inventors: Stephen E. Epstein, Toren Finkel, Edith Speir, Yi Fu Zhou, Jianhui Zhu, Lorne Erdile, Steven Pincus
  • Patent number: 6024963
    Abstract: An enhanced immune response to antigens, particularly normally weakly-immunogenic viral antigens, such as the HA antigen from influenza virus, is achieved by coadministering the antigen in two different physio-chemical forms, particularly to enable presentation of antigen both by B cells and accessory cells.
    Type: Grant
    Filed: November 17, 1998
    Date of Patent: February 15, 2000
    Assignee: Connaught Laboratories, Inc.
    Inventors: Robert S. Becker, Karen Biscardi, Laura Ferguson, Lorne Erdile
  • Patent number: 5853736
    Abstract: An enhanced immune response to antigens, particularly normally weakly-immunogenic viral antigens, such as the HA antigen from influenza virus, is achieved by coadministering the antigen in two different physiochemical forms, particularly to enable presentation of antigen both by B cells and accessory cells.
    Type: Grant
    Filed: February 18, 1997
    Date of Patent: December 29, 1998
    Assignee: Connaught Laboratories, Inc.
    Inventors: Robert S. Becker, Karen Biscardi, Laura Ferguson, Lorne Erdile
  • Patent number: 5837264
    Abstract: An enhanced immune response to antigens, particularly normally weakly-immunogenic viral antigens, such as the HA antigen from influenza virus, is achieved by coadministering the antigen in two different physio-chemical forms, particularly to enable presentation of antigen both by B cells and accessory cells.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 17, 1998
    Assignee: Connaught Laboratories, Inc.
    Inventors: Robert S. Becker, Karen Biscardi, Laura Ferguson, Lorne Erdile
  • Patent number: 5686078
    Abstract: Animals, including humans, are immunized by antigens, for example, the HA antigen of influenza, by first administering to a naive animal a normally strongly-immunogenic form of the antigen, for example, inactiviated or attenuated whole cell virus and subsequently administering a normally weakly-immunogenic isolated and purified viral antigen, to achieve an enhanced immune response to the purified viral antigen.
    Type: Grant
    Filed: February 8, 1995
    Date of Patent: November 11, 1997
    Assignee: Connaught Laboratories, Inc.
    Inventors: Robert S. Becker, Laura Ferguson, Lorne Erdile, Maurice W. Harmon, Robert Huebner
  • Patent number: 5683702
    Abstract: Animals, including humans, are immunized by antigens, for example, the HA antigen of influenza, by first administering to a naive animal a normally strongly-immunogenic form of the antigen, for example, inactivated or attenuated whole cell virus and subsequently administering a normally weakly-immunogenic isolated and purified viral antigen, to achieve an enhanced immune response to the purified viral antigen.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 4, 1997
    Assignee: Connaught Laboratories, Inc.
    Inventors: Robert S. Becker, Laura Ferguson, Lorne Erdile, Maurice W. Harmon, Robert Huebner
  • Patent number: 5662909
    Abstract: An enhanced immune response to antigens, particularly normally weakly-immunogenic viral antigens, such as the HA antigen from influenza virus, is achieved by coadministering the antigen in two different physio-chemical forms, particularly to enable presentation of antigen both by B cells and accessory cells.
    Type: Grant
    Filed: February 8, 1995
    Date of Patent: September 2, 1997
    Assignee: Connaught Laboratories, Inc.
    Inventors: Robert S. Becker, Karen Biscardi, Laura Ferguson, Lorne Erdile